A synthetic 39-amino-acid research peptide in the GIP/GLP-1 dual-agonist class — a two-target incretin compound. A solid, supplied as a single-lot reference material.
Vial size
$48.00
10 mg / vial · $4.80 / mg
Quantity
Add 1 more for 3% off
Bundle & save
1 vial
$48.00
each
2 vials
$46.56
3% off
3+ vials
$45.60
5% off
Per-vial price shown. The discount applies automatically at checkout.
Purchase options
Verification
Every batch is identified by a lot number, and its third-party certificate is listed here by lot. Measured values are shown only when they are real and independently verifiable.
Third-party testing in progress
We are currently having this product independently tested by a third-party laboratory. Its certificate of analysis will be published here as soon as the results are available — please check back soon. For laboratory research use only.
Tirzepatide is a synthetic research peptide of thirty-nine amino acids in the GIP/GLP-1 dual-agonist class — a two-target compound in the incretin research collection.
We stock it as a single-lot reference standard, characterized for third-party analysis, with the certificate for your lot published on release to its verification page.
Its interest is its class and its place in the collection: a two-target incretin compound that sits between the single-target and triple-target reference peptides researchers line up beside it. Purity is stated as one specification and verified for each lot.
For laboratory research use only. Not for human or veterinary use.
Tirzepatide is a dual agonist at the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, a two-target incretin analogue. It is catalogued in incretin and metabolic-pathway research as a reference point between single- and triple-target compounds.
Independent peer-reviewed literature that references Tirzepatide.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock J et al.
Lancet2021
View source for Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (opens in a new tab)Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction
Nauck MA et al.
Cardiovasc Diabetol2022
View source for Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction (opens in a new tab)Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Loomba R et al.
N Engl J Med2024
View source for Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (opens in a new tab)Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
Zhao L et al.
JAMA2024
View source for Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial (opens in a new tab)Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM et al.
N Engl J Med2025
View source for Tirzepatide for Obesity Treatment and Diabetes Prevention (opens in a new tab)Citations are provided for educational and scientific reference only. They describe independent published research and are not product claims — they do not represent the performance, purity, or intended use of any material offered for sale.
General handling guidance for laboratory research materials — always defer to the product label and the lot certificate of analysis.
Research use only
For laboratory research use only. Not for human or veterinary use.
No reviews yet
Reviews are published only from verified purchases, so none appear until orders ship.
Peptide
A short synthetic peptide corresponding to a tail-end fragment of human growth hormone, with one extra building block added at the front.
Peptide
A synthetic peptide of fifteen building blocks (a pentadecapeptide), based on a partial sequence of a protein first identified in gastric juice.
Peptide blend
A blend of two peptides — BPC-157 and TB-500 — supplied together. A mixture, not a single substance, with no identity of its own.
Peptide
A growth-hormone-releasing factor analogue of twenty-nine building blocks, also known as Modified GRF (1-29). Easily confused with the closely related sermorelin.